Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 32 | 2023 | 102 | 7.990 |
Why?
|
| Sarcoma | 15 | 2023 | 65 | 3.120 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 24 | 2.020 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 11 | 1.750 |
Why?
|
| Bone Substitutes | 8 | 2017 | 25 | 1.720 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 5 | 1.560 |
Why?
|
| Bone Transplantation | 6 | 2017 | 224 | 1.240 |
Why?
|
| Calcium Sulfate | 5 | 2012 | 19 | 1.120 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 41 | 1.010 |
Why?
|
| Limb Salvage | 5 | 2023 | 8 | 0.990 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3273 | 0.880 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 184 | 0.880 |
Why?
|
| Humans | 56 | 2023 | 29361 | 0.840 |
Why?
|
| Hip Joint | 2 | 2016 | 367 | 0.820 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 7 | 0.790 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 25 | 0.740 |
Why?
|
| Fractures, Bone | 2 | 2012 | 75 | 0.700 |
Why?
|
| Osteosarcoma | 6 | 2021 | 29 | 0.690 |
Why?
|
| Child, Preschool | 9 | 2021 | 641 | 0.690 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 2 | 0.690 |
Why?
|
| Young Adult | 12 | 2021 | 1935 | 0.680 |
Why?
|
| Adult | 21 | 2022 | 8604 | 0.680 |
Why?
|
| Adolescent | 15 | 2021 | 2280 | 0.680 |
Why?
|
| Tibia | 2 | 2010 | 259 | 0.650 |
Why?
|
| Child | 11 | 2021 | 1345 | 0.620 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.590 |
Why?
|
| Treatment Outcome | 15 | 2023 | 3476 | 0.580 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.570 |
Why?
|
| Foot | 1 | 2016 | 30 | 0.560 |
Why?
|
| Arthrodesis | 2 | 2014 | 40 | 0.560 |
Why?
|
| Internal Fixators | 1 | 2016 | 54 | 0.560 |
Why?
|
| Acetabulum | 3 | 2016 | 208 | 0.560 |
Why?
|
| Foreign Bodies | 1 | 2016 | 25 | 0.560 |
Why?
|
| Radiotherapy | 1 | 2016 | 50 | 0.550 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 42 | 0.550 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 696 | 0.540 |
Why?
|
| Middle Aged | 19 | 2021 | 9823 | 0.540 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 63 | 0.540 |
Why?
|
| Male | 24 | 2021 | 15637 | 0.520 |
Why?
|
| Radius | 2 | 2014 | 32 | 0.520 |
Why?
|
| Female | 21 | 2021 | 16211 | 0.470 |
Why?
|
| Survival Rate | 5 | 2021 | 349 | 0.470 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 248 | 0.470 |
Why?
|
| Arthralgia | 2 | 2011 | 121 | 0.440 |
Why?
|
| Biopsy | 5 | 2023 | 234 | 0.430 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 364 | 0.410 |
Why?
|
| Prognosis | 8 | 2023 | 840 | 0.400 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.400 |
Why?
|
| Talus | 1 | 2011 | 10 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 56 | 0.400 |
Why?
|
| Allografts | 4 | 2021 | 180 | 0.400 |
Why?
|
| Edema | 1 | 2011 | 38 | 0.390 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1829 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 34 | 0.380 |
Why?
|
| Patellar Ligament | 1 | 2010 | 52 | 0.380 |
Why?
|
| Chondrosarcoma | 3 | 2023 | 31 | 0.370 |
Why?
|
| Humerus | 3 | 2005 | 98 | 0.360 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 625 | 0.340 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 558 | 0.340 |
Why?
|
| Femur | 4 | 2022 | 398 | 0.330 |
Why?
|
| Bone Plates | 1 | 2008 | 54 | 0.320 |
Why?
|
| Reoperation | 6 | 2022 | 933 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 53 | 0.300 |
Why?
|
| Cisplatin | 3 | 2017 | 91 | 0.290 |
Why?
|
| Osteogenesis | 1 | 2007 | 99 | 0.290 |
Why?
|
| Tobramycin | 1 | 2005 | 9 | 0.270 |
Why?
|
| Curettage | 3 | 2022 | 5 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 864 | 0.260 |
Why?
|
| Aged | 10 | 2021 | 9447 | 0.260 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 175 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 75 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 402 | 0.250 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 391 | 0.250 |
Why?
|
| Margins of Excision | 2 | 2022 | 17 | 0.250 |
Why?
|
| Infant | 3 | 2021 | 531 | 0.240 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 81 | 0.240 |
Why?
|
| Joint Instability | 1 | 2008 | 387 | 0.240 |
Why?
|
| Pelvic Bones | 1 | 2004 | 20 | 0.240 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 26 | 0.230 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 36 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 60 | 0.230 |
Why?
|
| Knee Joint | 2 | 2008 | 797 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 340 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4851 | 0.220 |
Why?
|
| Plasma Gases | 1 | 2022 | 1 | 0.220 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 167 | 0.220 |
Why?
|
| Neutrophils | 1 | 2023 | 117 | 0.220 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 3 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 770 | 0.210 |
Why?
|
| Infant, Newborn | 2 | 2021 | 604 | 0.210 |
Why?
|
| Bone Cements | 3 | 2022 | 99 | 0.210 |
Why?
|
| Apoptosis | 5 | 2022 | 251 | 0.210 |
Why?
|
| Radiography | 5 | 2015 | 678 | 0.200 |
Why?
|
| Debridement | 2 | 2012 | 100 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 6 | 0.200 |
Why?
|
| Myxosarcoma | 1 | 2020 | 2 | 0.200 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 3 | 0.190 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 1 | 0.190 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 7 | 0.190 |
Why?
|
| Orthopedics | 1 | 2002 | 127 | 0.190 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 18 | 0.180 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 215 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 606 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 265 | 0.170 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 13 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 218 | 0.170 |
Why?
|
| Dogs | 4 | 2007 | 253 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2019 | 32 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 67 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 75 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 89 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 76 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 101 | 0.160 |
Why?
|
| Osteoarthritis | 1 | 2022 | 363 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 47 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 290 | 0.150 |
Why?
|
| Imidazoles | 1 | 2017 | 72 | 0.150 |
Why?
|
| Piperazines | 1 | 2017 | 90 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Synovectomy | 1 | 2016 | 4 | 0.140 |
Why?
|
| Child Development | 1 | 2016 | 71 | 0.140 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 6 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1939 | 0.130 |
Why?
|
| Supination | 1 | 2014 | 18 | 0.130 |
Why?
|
| Disease Management | 1 | 2016 | 114 | 0.130 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 113 | 0.130 |
Why?
|
| Osteomyelitis | 2 | 2005 | 22 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 33 | 0.130 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 42 | 0.130 |
Why?
|
| Prosthesis Design | 3 | 2022 | 502 | 0.130 |
Why?
|
| Arthroplasty | 1 | 2016 | 136 | 0.130 |
Why?
|
| Chondroma | 2 | 2012 | 3 | 0.130 |
Why?
|
| Lung | 1 | 2015 | 154 | 0.130 |
Why?
|
| Hand Strength | 1 | 2014 | 59 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 61 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 524 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 2446 | 0.120 |
Why?
|
| Time Factors | 2 | 2022 | 1618 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2013 | 2 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1220 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 516 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Bone Cysts | 1 | 2012 | 1 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2012 | 290 | 0.110 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 4 | 0.110 |
Why?
|
| Bone Matrix | 2 | 2003 | 28 | 0.110 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 28 | 0.110 |
Why?
|
| beta Catenin | 1 | 2013 | 46 | 0.110 |
Why?
|
| Bone Regeneration | 2 | 2003 | 73 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 21 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 39 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 389 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 699 | 0.100 |
Why?
|
| Ankle | 1 | 2011 | 17 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 100 | 0.100 |
Why?
|
| Thoracoscopy | 1 | 2010 | 16 | 0.100 |
Why?
|
| Ilium | 1 | 2010 | 31 | 0.100 |
Why?
|
| Orthopedic Procedures | 2 | 2004 | 317 | 0.090 |
Why?
|
| Animals | 5 | 2007 | 4577 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 340 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 845 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 521 | 0.090 |
Why?
|
| Chicago | 1 | 2012 | 865 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2008 | 298 | 0.080 |
Why?
|
| Compressive Strength | 1 | 2007 | 28 | 0.080 |
Why?
|
| Elasticity | 1 | 2007 | 39 | 0.080 |
Why?
|
| Injections | 1 | 2007 | 56 | 0.080 |
Why?
|
| Illinois | 1 | 2008 | 241 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2023 | 1812 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 30 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 58 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 108 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 73 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 97 | 0.070 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 15 | 0.070 |
Why?
|
| Drug Implants | 1 | 2005 | 11 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2016 | 159 | 0.060 |
Why?
|
| Telomerase | 1 | 2004 | 9 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 324 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 437 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Cell Division | 2 | 2022 | 114 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 38 | 0.060 |
Why?
|
| Arthroscopy | 1 | 2011 | 811 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 101 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2023 | 49 | 0.060 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 14 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 35 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 64 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2023 | 135 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2023 | 110 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2004 | 277 | 0.060 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 104 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 5 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 483 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 117 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 32 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 48 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 37 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 88 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 45 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 38 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 68 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 678 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 30 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 383 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 8 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 45 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 49 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 78 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 10 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 63 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 162 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 6 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 33 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 41 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 64 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 109 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 10 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 26 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 127 | 0.030 |
Why?
|
| Proteoglycans | 1 | 1992 | 337 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 10 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 55 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 16 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 112 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 76 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 169 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 145 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.020 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 175 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 126 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 197 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 255 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 726 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 5 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 9 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 10 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 10 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 9 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 25 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 32 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 106 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 74 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 218 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 146 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 676 | 0.010 |
Why?
|